Product Overview
AOD-9604 (often searched as AOD-9064) is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically mapping to amino acid residues 177-191, with an additional tyrosine residue incorporated at the N-terminus to stabilise the molecule. Researchers utilise this compound in laboratory models to investigate lipid metabolism, specifically targeted lipolysis, independent of the classical endocrine pathways associated with full-length hGH.
Synthesised to strict analytical standards, this compound exhibits exceptional structural integrity, ensuring accurate experimental replication in diverse in vitro and animal model assays. It serves as an essential reagent for scientific investigations requiring precise modulation of adipocyte metabolic activity without inducing off-target receptor activation or altering ambient glucose homeostasis.
Technical Specifications
- Chemical Name: Tyr-hGH (177-191)
- CAS Number: 221231-10-3
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly
- Molecular Formula: C78H123N23O23S2
- Molecular Weight: 1815.1 g/mol
- Target: Adipocyte β3-adrenergic receptors / Lipolytic pathways
- Mechanism: Upregulation of lipolysis and inhibition of lipogenesis
- Half-Life: Approximately 3-4 hours (animal models)
- Format: Lyophilised Solid
- Appearance: White crystalline powder
- Grade: Laboratory / Analytical Grade
- Purity: >99% HPLC Verified
Variant Breakdown
- 2mg Lyophilised Vial
- 5mg Lyophilised Vial
- 10mg Lyophilised Vial
- Closure: Rubber stopper with flip-off aluminium seal.
Research Mechanism (Mechanism of Action)
In laboratory models, AOD-9604 directly influences lipid metabolism by stimulating lipolysis and inhibiting lipogenesis. Its functional mechanism partially mimics the physiological actions of the full-length parent hormone but remains constrained strictly to adipocyte regulation. Experimental data indicates that the peptide fragment interacts with the β3-adrenergic pathway, which mediates the breakdown of triglycerides into free fatty acids and glycerol within adipose tissue.
Subsequent cellular assays demonstrate that AOD-9604 upregulates the transcription of β3-adrenergic receptor RNA in isolated adipocytes. By increasing the expression density of these receptors, the peptide enhances the sensitivity of the cellular environment to endogenous lipolytic stimuli. Notably, animal models exposed to the fragment exhibit elevated fatty acid oxidation rates without the corresponding hyperinsulinemia or insulin resistance typically induced by intact hGH administration.
Safety, Handling & Reconstitution
For optimum solubility and preservation of the peptide sequence, researchers must reconstitute the lyophilised solid using Bacteriostatic Reconstitution Solution (0.9% Benzyl Alcohol). Allow the vial to equilibrate to ambient room temperature prior to mixing. Inject the solvent slowly against the inner glass wall, rotating the vial gently to achieve complete dissolution while avoiding violent agitation that could denature the disulfide bridge.
Store the unmixed lyophilised solid in a desiccated state at -20°C out of direct light. Following reconstitution, solutions require immediate refrigeration between 2°C to 8°C to maintain structural stability throughout the duration of the experimental protocol. Strictly restricted to Laboratory Research Purposes Only.
Scientific References (External Links)
Drug Testing and Analysis: “Detection and in vitro metabolism of AOD9604” View Study
Endocrinology: “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice” View Study
Hormone Research: “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone” View Study
Current Opinion in Investigational Drugs: “AOD-9604 Metabolic” View Study
